Health
-
Prescient Therapeutics targets cancer with world-first GGTase-1 inhibitor
Prescient is at the forefront of targeted cancer treatment with its lead drug candidate PTX-100, the world’s…
-
Entropy’s IV-psilocin candidate will go up against widely used antidepressant in proposed Phase II trial
Entropy Neurodynamics signs a pre-Clinical Trial Agreement with the University of California, San Francisco (UCSF) to undertake…
-
Imagion advances HER2 breast cancer trial towards US enrolment
With CRO work orders signed and the imaging agent manufactured, seven prospective US sites are now being…
-
Health Check: Genetic Signatures and Microba talk merger as BCAL crashes the romance
Genetic Signatures and Microba are discussing a merger to create an ASX leader in gastrointestinal conditions. But…
-
Biocurious: Calmer Co aims to kava-out a niche in sober-curious US
With alcohol consumption at close to a century low in the US, The Calmer Co eyes massive…